Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Daxxify
Daxxify
AbbVie expects Botox to maintain market share as competition heats up
Reuters
Wed, 01/10/24 - 06:24 pm
AbbVie
aesthetics
Botox
Evolus
Jeuveau
Revance Therapeutics
Daxxify
US consumer group seeks stronger warnings on Botox, similar treatments
Reuters
Tue, 12/12/23 - 10:02 am
Public Citizen
FDA
Botox
AbbVie
Revance Therapeutics
Daxxify
Evolus
Jeuveau
Supernus Pharmaceuticals
Myobloc
Galderma
Dysport
Revance rolls out a price drop for Daxxify as it tries to challenge AbbVie's Botox
Fierce Pharma
Wed, 09/20/23 - 08:57 am
Revance Therapeutics
Daxxify
AbbVie
Botox
drug pricing
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
BioSpace
Mon, 08/14/23 - 11:29 am
FDA
Ipsen
Revance Therapeutics
Neurocrine
Regeneron
palovarotene
fibrodysplasia ossificans progressiva
Daxxify
cervical dystonia
Ingrezza
chorea
Huntington's disease
pozelimab
CHAPLE disease
Revance wants you to 'Break Up With Botox' as it goes to war with AbbVie in new anti-wrinkle market battle
Fierce Pharma
Mon, 07/3/23 - 10:44 am
Revance Therapeutics
Daxxify
pharma marketing
AbbVie
Botox
Goldman Sachs says this biotech working on a Botox rival drug could rally nearly 30%
CNBC
Fri, 09/23/22 - 10:52 am
Revance Therapeutics
Botox
aesthetics
Daxxify
AbbVie unveils 'See Yourself' Botox campaign, days after new rival approved
Endpoints
Tue, 09/13/22 - 08:06 pm
AbbVie
Allergan
Botox
DTC ads
Daxxify
Revance Therapeutics
Longer-lasting Botox competitor nabs FDA approval — can it compete with AbbVie's $2B cash cow?
Endpoints
Thu, 09/8/22 - 11:04 am
Revance Therapeutics
FDA
Daxxify
aesthetics
AbbVie
Botox